- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04122469
The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease (RADIANT)
Systemic therapy is the main treatment for patients with metastatic cancers. Oligo-progression has become a recognized entity for metastatic cancer and it is thought that a subset of cancer cells may develop heterogeneity and resistant clones while receiving systemic therapy. This results in overall tumor response but progression in metastatic sites. Current standard is to change systemic therapies. With advancing technologies, stereotactic body radiation therapy is being used to deliver high doses of focused radiation to the disease site, while minimizing risk of injury to the surrounding organs. SBRT is increasingly being used in patients presenting oligo-metastatic disease, and is recognized as having a potential for cure. This study will investigate the use of SBRT for breast and genito-urinary cancer patients with oligo-progression. Patients will be seen before and at the end of treatment and will be followed at 4 month intervals for up to 2 years.
During the visits participants will complete quality of life questionnaires and will have standard of care imaging.
Patients will also have the option to provide blood at baseline, during treatment, and at various follow up time points for analysis of ctDNA
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rachel Glicksman, MD
- Phone Number: 416-946-4961
- Email: rachel.glicksman@uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- Princess Margaret Cancer Centre
-
Contact:
- Rachel Glicksman, MD
- Phone Number: 416-946-4961
- Email: rachel.glicksman@uhn.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult patients ≥18 years accrued at the Princess Margaret Cancer Centre
5 or less sites of intra or extra-cranial oligo-progressive, de novo oligo-metastatic, induced oligo-metastatic and repeat oligo-metastatic breast disease amenable to ablative treatment (including but not limited to radiotherapy, surgery, radio-frequency ablation);
o at least one lesion should be planned for SBRT
- OR 5 or less sites of intra or extra-cranial oligo-progressive prostate, bladder and renal cell carcinomas
- Tumor mass amenable to SABR (≤6cm in size)
Confirmation of diagnosis:
- Known/documented prior histological (for all excluding HCC) or radiological diagnosis (for HCC) of:
- Pathologically confirmed breast cancer OR,
- Pathologically confirmed GU cancer (such as prostate cancer, bladder cancer, or radiologically or pathologically confirmed RCC).
- For prostate patients only: Known metastatic disease treated with ADT (patients who received other ST as first line treatment of mCSPC would be eligible; eg Docetaxel, Abiraterone…)
- For prostate patients only: Known metastatic CRPC progressing on ST (Docetaxel, Abiraterone, Enzalutamide…)
For oligo-progressive disease: receiving any form of ST for at least 3 months with (ST breaks are permitted):
Radiographic evidence of ≤3 intra or extra-cranial lesions progressing (including nodal or distant). At least one lesion is suitable for SBRT. Each progressing lesion should fulfill at least 1 of the 3 following criteria for oligo-progression:
- Progression of a metastasis according to RECIST 1.1 criteria7
- Unambiguous development of a new lesion from the time of scan taken prior to starting ST
- Progressive enlargement of a known metastasis on 2 consecutive imaging (CT or MRI) 2-3 months apart, while on ST, with a minimum 5 mm increase in size from baseline.
- Remainder of metastatic disease stable or regressing, as per RECIST v1.1, evidenced by >2 consecutive images within the past 4-6 months.
- Able to provide written consent
- ECOG performance status 0-3
Exclusion Criteria:
- ≥6 progressive metastases
- Evidence of spinal cord compression or acute event requiring urgent/emergency radiotherapy
- Prior radiotherapy, with fields overlapping, resulting in excessive doses to organs at risk
- Previous radical RT in the area of OP
- Inability to safely treat all sites of progressing metastases
- Patient cannot tolerate physical set-up required for SBRT
- Treatment plan respecting normal tissue tolerances using dose fractionation specified within the protocol cannot be achieved
- Active bowel obstruction, if treating abdominal/pelvic site
- Neuroendocrine, lymphoma, myeloma or germ cell malignancies
- Familial syndromes: Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary RCC or Tuberous Sclerosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oligo-Progression; GU
Receiving SBRT.
|
The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population
|
Experimental: Oligo-metastatic Breast Cancer
Receiving SBRT.
|
The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of SBRT in OP malignancies
Time Frame: 24 month period
|
To determine the safety of SBRT in OP malignancies over a 24-month follow-up period using CTCAE v5.0.
|
24 month period
|
Efficacy of SBRT in OP malignancies
Time Frame: 24 month period
|
To determine the efficacy of SBRT in OP malignancies over a 24-month follow-up period by evaluating progression-free survival.
Radiographic local control of irradiated areas and local disease will also be used to determine efficacy by using Response Evaluation Criteria in Solid Tumors (RECIST).
|
24 month period
|
Feasibility of SBRT in OP malignancies
Time Frame: 24 month period
|
To determine the feasibility of SBRT in OP malignancies over a 24-month follow-up period using the a quality of life questionnaire (the EORTC QLQ-C30 questionnaire).
|
24 month period
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Metastatic
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
Clinical Trials on Stereotactic Body Radiotherapy
-
Mercy ResearchCompletedNasopharyngeal Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Salivary Gland Cancer | Paraganglioma of Head and Neck | Head and Neck Sarcoma | Chordoma of Head and Neck | Chondrosarcoma of Head and Neck | Angiofibroma of Head and NeckUnited States
-
The Netherlands Cancer InstituteCompletedLung Cancer | Metastatic Lung CancerNetherlands, United States, Canada, Germany
-
University of FloridaDiaCarta, Inc.Terminated
-
European Organisation for Research and Treatment...UnknownNon-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIGermany, Belgium, United Kingdom, Switzerland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)TerminatedNon-small-cell Lung CancerUnited States
-
Mayo ClinicActive, not recruitingProstate CancerUnited States
-
UMC UtrechtCompletedBone Metastases | Spinal MetastasesNetherlands
-
National Taiwan University HospitalUnknownMetastasis of Malignant Neoplasm to Lymph NodeTaiwan
-
Maria Sklodowska-Curie National Research Institute...RecruitingRadiotherapy | Local Recurrence of Malignant Tumor of ProstatePoland
-
Linda Chan, MDRecruiting